St Louis, Missouri
Phase 1 colorectal cancer trials in St Louis, MO
30 Phase 1 colorectal cancer studies are recruiting participants at sites in St Louis as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
St Louis at a glance
- 30 studies are recruiting at a site in St Louis.
- By phase: Phase 1 (15), Phase 1/2 (15).
- By sponsor: industry (26), university, hospital or other (3), government (1).
- Most recent update to one of these records: November 17, 2026.
Studies recruiting in St Louis
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Washington University
- Registry record
- NCT05786924 · updated
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- Washington University School of Medicine
- Registry record
- NCT06253871 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- Washington University Medicine
- Registry record
- NCT06270706 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Washington University School of Medicine
- Registry record
- NCT07020221 · updated
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Washington University
- Registry record
- NCT07114601 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Washington University School of Medicine in St. Louis
- Registry record
- NCT07213791 · updated
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Siteman Cancer Center
- Registry record
- NCT07397338 · updated
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Sairopa B.V.
- Study site
- Washington University Medical Campus
- Registry record
- NCT05856981 · updated
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Washington University School of Medicine in St. Louis
- Registry record
- NCT07416552 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- Washington University School of Medicine at St Louis
- Registry record
- NCT03526835 · updated
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Inc
- Study site
- Washington University School of Medicine
- Registry record
- NCT07094204 · updated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- Saint Louis University
- Registry record
- NCT06710756 · updated
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Alterome Therapeutics, Inc.
- Registry record
- NCT06835569 · updated
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Study site
- Washington University
- Registry record
- NCT06973564 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study site
- Washington University
- Registry record
- NCT04657068 · updated
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kura Oncology, Inc.
- Study site
- Washington University School of Medicine
- Registry record
- NCT06026410 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- Washington University School of Medicine
- Registry record
- NCT05919264 · updated
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study site
- Washington University School of Medicine
- Registry record
- NCT06625775 · updated
A Study of PHN-012 in Patients With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pheon Therapeutics
- Study site
- PHN-012-001 Site
- Registry record
- NCT07127874 · updated
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Angiex, Inc.
- Study site
- Washington University School of Medicine
- Registry record
- NCT06440005 · updated
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT06696768 · updated
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Phase 1/2
- From 12 months, up to 30 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Washington University School of Medicine
- Registry record
- NCT04851119 · updated
IDOV-Immune for Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- ViroMissile, Inc.
- Study site
- Washington University School of Medicine
- Registry record
- NCT06910657 · updated
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Amgen
- Study site
- Siteman Cancer Center - Washington University
- Registry record
- NCT07094113 · updated
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- MOMA Therapeutics
- Registry record
- NCT06974110 · updated
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Recursion Pharmaceuticals Inc.
- Study site
- Washington University School of Medicine
- Registry record
- NCT05552755 · updated
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Turning Point Therapeutics, Inc.
- Study site
- Washington University Infusion Center Pharmacy
- Registry record
- NCT03093116 · updated
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tasca Therapeutics
- Study site
- Washington University
- Registry record
- NCT07030257 · updated
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Washington University School of Medicine
- Registry record
- NCT03516708 · updated
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- A2 Biotherapeutics Inc.
- Study site
- Washington University
- Registry record
- NCT06682793 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Ask about studies near St Louis
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections